PTC Therapeutics, Inc. $PTCT Shares Sold by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. trimmed its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 15.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 91,136 shares of the biopharmaceutical company’s stock after selling 16,620 shares during the period. Hillsdale Investment Management Inc. owned about 0.11% of PTC Therapeutics worth $5,593,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PTCT. Ameritas Investment Partners Inc. increased its position in shares of PTC Therapeutics by 3.0% in the second quarter. Ameritas Investment Partners Inc. now owns 7,936 shares of the biopharmaceutical company’s stock worth $388,000 after acquiring an additional 231 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 236 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of PTC Therapeutics by 42.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 295 shares during the period. Arizona State Retirement System lifted its position in PTC Therapeutics by 2.0% during the 3rd quarter. Arizona State Retirement System now owns 21,101 shares of the biopharmaceutical company’s stock worth $1,295,000 after acquiring an additional 406 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its holdings in PTC Therapeutics by 2.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 19,123 shares of the biopharmaceutical company’s stock worth $934,000 after acquiring an additional 442 shares during the period.

Insider Activity

In other PTC Therapeutics news, CAO Christine Marie Utter sold 2,494 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total transaction of $172,983.84. Following the sale, the chief accounting officer directly owned 70,199 shares of the company’s stock, valued at approximately $4,869,002.64. This represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Mark Elliott Boulding sold 3,081 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $213,698.16. Following the completion of the transaction, the vice president owned 108,231 shares in the company, valued at approximately $7,506,902.16. The trade was a 2.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 298,246 shares of company stock valued at $23,393,870 over the last quarter. 5.50% of the stock is owned by company insiders.

PTC Therapeutics Stock Performance

NASDAQ:PTCT opened at $70.66 on Friday. The company has a market capitalization of $5.67 billion, a price-to-earnings ratio of 9.13 and a beta of 0.48. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50. The stock has a 50-day simple moving average of $74.91 and a 200 day simple moving average of $68.02.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). The firm had revenue of $164.68 million for the quarter, compared to the consensus estimate of $281.45 million. PTC Therapeutics had a negative return on equity of 373.67% and a net margin of 39.44%.The company’s quarterly revenue was down 22.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.85) EPS. On average, equities research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Analyst Ratings Changes

PTCT has been the topic of a number of analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Wells Fargo & Company lowered their price target on shares of PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating for the company in a report on Friday. Jefferies Financial Group boosted their price objective on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Bank of America lowered their target price on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research note on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of PTC Therapeutics in a research note on Friday. Ten equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.73.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.